Brain cell injection could tame Drug-Resistant epilepsy

NCT ID NCT07572812

Not yet recruiting Disease control Sponsor: Shanghai UniXell Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This early-stage trial tests a new cell therapy called UX-GIP001 for adults with drug-resistant temporal lobe epilepsy. The treatment involves injecting special brain cells into the seizure area to calm overactive nerves. Only 12 people will take part, and the main goal is to check safety and see if seizures decrease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: UX-GIP001 (human GABAergic interneuron progenitor cells)
What this could lead to: If successful, this could point toward a new treatment option for people with drug-resistant epilepsy, potentially reducing or stopping seizures.
What could go wrong: This is a very early Phase 1 trial with only 12 participants, so safety and effectiveness are not yet proven. The cell injection into the brain carries surgical risks, and participants may need lifelong immunosuppression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG-RESISTANT UNILATERAL MESIAL TEMPORAL LOBE EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epilepsy mesial temporal lobe epilepsy with hippocampal sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPILEPSY

Contacts and locations

Locations

Beijing Tiantan Hospital, Capital Medical University

Beijing, Beijing Municipality, 100070, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450000, China
West China School of Medicine and West China Hospital, Sichuan University

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.